Stevanato Group S.p.A. (STVN) Stock Analysis and Metrics

Stevanato Group S.p.A

NYSE: STVN

$19.73 ▲ +0.33 (+1.68%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap5.36 Bn

P/E96.91

P/S3.85

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)529.28 Mn

Revenue Growth (1y) (Qtr)18.66

Add ratio to table…

About

Stevanato Group S.p. A. is a leading global provider of drug containment, drug delivery, and diagnostic solutions, together with engineering solutions, for the pharmaceutical, biotechnology, and life sciences industries. The company offers an integrated, end to end portfolio that supports customers across the entire drug product life cycle, from research and development through commercialization.

Revenue is generated primarily through the sale of drug containment products such as prefillable syringes, vials, cartridges and ampoules; drug delivery systems including autoinjectors, pen injectors and onbody delivery systems; diagnostic consumables and equipment; and engineering machinery for assembly, packaging, visual inspection and glass converting. In 2025, approximately 88 % of total revenue came from the Biopharmaceutical and Diagnostic Solutions segment and the remaining 12 % from the Engineering segment. Customers are mainly pharmaceutical and biotechnology companies, as well as contract manufacturers and other life science firms.

The company operates through the following segments: Biopharmaceutical and Diagnostic Solutions and Engineering.

• Biopharmaceutical and Diagnostic Solutions: This segment provides drug containment solutions such as prefillable syringes, vials, cartridges and ampoules; drug delivery systems including autoinjectors, pen injectors and onbody delivery systems; diagnostic consumables and equipment; and related services such as analytical and regulatory support.

• Engineering: This segment designs, manufactures and sells machinery for assembly, packaging, visual inspection and glass converting, used in pharmaceutical, biotechnology and life sciences production processes.

Stevanato Group S.p. A. holds a leading position in the drug containment, delivery and diagnostic markets, ranking among the top three providers globally in several product lines such as prefillable syringes and ready to use vials. The company competes with firms such as Schott, Becton Dickinson, Gerresheimer, Nipro, West Pharmaceutical, SHL, Ypsomed and Syntegon. Its competitive advantages stem from an integrated end to end offering, a reputation for high quality and reliability, extensive research and development capabilities, and a global manufacturing footprint spanning approximately 65 countries.

Stevanato Group S.p. A. serves a diversified customer base of more than 700 companies worldwide, including 23 of the top 25 pharmaceutical corporations, six of the top ten in vitro diagnostic firms and seven of the top ten biotechnology businesses by market capitalization, as well as over 100 additional biotechnology customers and numerous contract manufacturers.

Investment Thesis

▲ Bull case

Stevanato Group is positioned to capitalize on the accelerating shift toward large-volume biologics, which is driving demand for high-capacity cartridges beyond traditional 1.5 ml and 3 ml formats to volumes up to 20 ml. This trend is underpinned by the industry-wide move toward subcutaneous delivery of high-potency monoclonal antibodies and other advanced therapies, which require larger drug loads per dose. The company’s strategic conversion of an underutilized ready-to-use vial line in Piombino Dese to a ready-to-use cartridge line—expected to enter commercial production in the coming weeks—demonstrates operational agility and directly addresses near-term supply constraints. This initiative, combined with the upcoming launch of next-generation RTU 400 EZ-fill cartridge lines in Latina slated for early 2027, creates a dual-track capacity expansion that not only meets current demand but also future-proofs the company against evolving customer needs. The fact that Stevanato is already fully booked on cartridge capacity for 2026, despite only recently converting the Piombino Dese line, signals that market demand is significantly outpacing current supply, creating a powerful pricing and utilization tailwind that is not yet fully reflected in investor expectations.
The company’s exposure to GLP-1 therapies, which now constitute 21% to 22% of total revenue, is more durable and less vulnerable to oral competition than the market perceives. Management’s internal data indicates that over 70% of the GLP-1 market opportunity remains in injectables, with orals representing only 30%—a split consistent with industry expert consensus. Furthermore, the majority of early oral adopters are new patients rather than switchers from injectables, suggesting market expansion rather than cannibalization. With over 150 million potential patients in the U.S. alone for obesity and diabetes indications, and a growing pipeline of novel indications beyond these areas (e.g., cardiovascular, neurodegenerative diseases), the long-term demand for injectable GLP-1 formulations is structurally supported. Stevanato’s leadership in both bulk and EZ-fill cartridges, coupled with recent biosimilar wins in this space, positions it to benefit from the upcoming wave of biosimilar GLP-1 entries as originator patents expire, which will expand access and volume without eroding Stevanato’s market share.
Stevanato’s Engineering segment, while currently underperforming due to low backlog and slow order conversion, is showing early signs of sustainable margin improvement driven by operational discipline rather than temporary cost cuts. The 460 basis point increase in gross profit margin in Q1 FY26—achieved through right-sizing operations, improved labor cost structure in Denmark, and a shift away from low-margin, complex custom projects—reflects a deliberate strategic pivot toward higher-margin, repeatable business such as pharmaceutical visual inspection and assembly for self-administration devices. This shift is not merely cyclical; it represents a structural upgrade in the segment’s quality of earnings. With sales and marketing investments underway in the U.S. and Europe, and a confirmed expectation of stronger second-half performance, the Engineering segment is poised to transition from a drag on profitability to a contributor of stable, mid-single-digit margin expansion by year-end. This turnaround, if realized, would significantly boost consolidated adjusted EBITDA margins beyond current guidance ranges, offering unappreciated upside to earnings quality.

Stevanato Group is positioned to capitalize on the accelerating shift toward large-volume biologics, which is driving demand for high-capacity cartridges beyond traditional 1.5 ml and 3 ml formats to volumes up to 20 ml. This trend is underpinned by the industry-wide move toward subcutaneous delivery of high-potency monoclonal antibodies and other advanced therapies, which require larger drug loads per dose. The company’s strategic conversion of an underutilized ready-to-use vial line in Piombino Dese to a ready-to-use cartridge line—expected to enter commercial production in the coming weeks—demonstrates operational agility and directly addresses near-term supply constraints. This initiative, combined with the upcoming launch of next-generation RTU 400 EZ-fill cartridge lines in Latina slated for early 2027, creates a dual-track capacity expansion that not only meets current demand but also future-proofs the company against evolving customer needs. The fact that Stevanato is already fully booked on cartridge capacity for 2026, despite only recently converting the Piombino Dese line, signals that market demand is significantly outpacing current supply, creating a powerful pricing and utilization tailwind that is not yet fully reflected in investor expectations.
The company’s exposure to GLP-1 therapies, which now constitute 21% to 22% of total revenue, is more durable and less vulnerable to oral competition than the market perceives. Management’s internal data indicates that over 70% of the GLP-1 market opportunity remains in injectables, with orals representing only 30%—a split consistent with industry expert consensus. Furthermore, the majority of early oral adopters are new patients rather than switchers from injectables, suggesting market expansion rather than cannibalization. With over 150 million potential patients in the U.S. alone for obesity and diabetes indications, and a growing pipeline of novel indications beyond these areas (e.g., cardiovascular, neurodegenerative diseases), the long-term demand for injectable GLP-1 formulations is structurally supported. Stevanato’s leadership in both bulk and EZ-fill cartridges, coupled with recent biosimilar wins in this space, positions it to benefit from the upcoming wave of biosimilar GLP-1 entries as originator patents expire, which will expand access and volume without eroding Stevanato’s market share.
Stevanato’s Engineering segment, while currently underperforming due to low backlog and slow order conversion, is showing early signs of sustainable margin improvement driven by operational discipline rather than temporary cost cuts. The 460 basis point increase in gross profit margin in Q1 FY26—achieved through right-sizing operations, improved labor cost structure in Denmark, and a shift away from low-margin, complex custom projects—reflects a deliberate strategic pivot toward higher-margin, repeatable business such as pharmaceutical visual inspection and assembly for self-administration devices. This shift is not merely cyclical; it represents a structural upgrade in the segment’s quality of earnings. With sales and marketing investments underway in the U.S. and Europe, and a confirmed expectation of stronger second-half performance, the Engineering segment is poised to transition from a drag on profitability to a contributor of stable, mid-single-digit margin expansion by year-end. This turnaround, if realized, would significantly boost consolidated adjusted EBITDA margins beyond current guidance ranges, offering unappreciated upside to earnings quality.

▼ Bear case

Stevanato Group’s reliance on GLP-1 therapies as a primary growth driver presents a concentrated risk that is underappreciated by investors, particularly given the accelerating pace of oral GLP-1 development and regulatory approvals. While management asserts that 70% of the GLP-1 market remains injectable, this assumption may be overly optimistic as newer oral formulations demonstrate improved bioavailability and patient adherence, potentially shifting the injectable/oral split faster than anticipated. The company’s guidance assumes mid-teens GLP-1 growth for FY26, but this is heavily dependent on contractual commitments from a limited number of large originators—any delay in biosimilar launches, slower-than-expected uptake of new indications, or a sudden shift toward oral dosing by major players could abruptly decelerate demand. Furthermore, the company’s disclosure that GLP-1 revenue includes customers with clinical-phase assets introduces visibility risk, as clinical trial failures or delays could abruptly remove near-term volume without warning, creating a hidden vulnerability in what is portrayed as a stable, long-term tailwind.
The capacity expansion initiatives in Latina and Fishers, while strategically sound, carry significant execution and timing risks that could undermine near-term financial performance. The conversion of the Piombino Dese vial line to cartridges is expected to enter commercial production in the coming weeks, but the company has not disclosed utilization rates or customer acceptance timelines for this line, raising concerns about potential underutilization if demand shifts or validation delays occur. More critically, the Latina RTU 400 EZ-fill cartridge line—slated for commercial production in early 2027—represents a major capital commitment with over 90% of Q1 FY26 capex tied to growth investments in Fishers and Latina. If demand for large-volume cartridges does not materialize as expected, or if competitors introduce alternative delivery systems (e.g., wearable injectors, advanced auto-injectors) that bypass traditional cartridge formats, Stevanato could face stranded assets and prolonged periods of low returns on invested capital. The current free cash flow of only EUR 5.5 million in Q1 FY26, despite EUR 75.5 million in operating cash flow, highlights the intense capital intensity of this expansion, leaving little margin for error if revenue growth falters.
The Engineering segment’s margin improvement, while real in Q1 FY26, is fragile and highly dependent on the successful delivery of legacy projects in Denmark and the avoidance of new low-margin, complex custom orders. Management’s optimism about returning to historical performance levels hinges on winning new business in visual inspection and self-administration assembly, yet order intake remains slower than expected despite increased sales and marketing efforts. The segment’s guidance assumes a mid-single-digit to low-double-digit revenue decline for FY26, implying that any further deterioration in order conversion—potentially driven by prolonged customer CapEx scrutiny, increased competition from automation specialists, or macroeconomic hesitation in industrial spending—could push margins back into negative territory. Moreover, the segment’s historical profitability was bolstered by non-recurring, high-margin projects (e.g., the Not for Human Use fill-and-finish service), which are not repeatable and whose decline in Q1 FY26 was explicitly cited as a headwind. Without a sustainable pipeline of high-margin, standardized offerings, the Engineering segment’s current margin gains may prove temporary, leaving the company exposed to a prolonged drag on consolidated profitability that could offset gains from the BDS segment.

Stevanato Group’s reliance on GLP-1 therapies as a primary growth driver presents a concentrated risk that is underappreciated by investors, particularly given the accelerating pace of oral GLP-1 development and regulatory approvals. While management asserts that 70% of the GLP-1 market remains injectable, this assumption may be overly optimistic as newer oral formulations demonstrate improved bioavailability and patient adherence, potentially shifting the injectable/oral split faster than anticipated. The company’s guidance assumes mid-teens GLP-1 growth for FY26, but this is heavily dependent on contractual commitments from a limited number of large originators—any delay in biosimilar launches, slower-than-expected uptake of new indications, or a sudden shift toward oral dosing by major players could abruptly decelerate demand. Furthermore, the company’s disclosure that GLP-1 revenue includes customers with clinical-phase assets introduces visibility risk, as clinical trial failures or delays could abruptly remove near-term volume without warning, creating a hidden vulnerability in what is portrayed as a stable, long-term tailwind.
The capacity expansion initiatives in Latina and Fishers, while strategically sound, carry significant execution and timing risks that could undermine near-term financial performance. The conversion of the Piombino Dese vial line to cartridges is expected to enter commercial production in the coming weeks, but the company has not disclosed utilization rates or customer acceptance timelines for this line, raising concerns about potential underutilization if demand shifts or validation delays occur. More critically, the Latina RTU 400 EZ-fill cartridge line—slated for commercial production in early 2027—represents a major capital commitment with over 90% of Q1 FY26 capex tied to growth investments in Fishers and Latina. If demand for large-volume cartridges does not materialize as expected, or if competitors introduce alternative delivery systems (e.g., wearable injectors, advanced auto-injectors) that bypass traditional cartridge formats, Stevanato could face stranded assets and prolonged periods of low returns on invested capital. The current free cash flow of only EUR 5.5 million in Q1 FY26, despite EUR 75.5 million in operating cash flow, highlights the intense capital intensity of this expansion, leaving little margin for error if revenue growth falters.
The Engineering segment’s margin improvement, while real in Q1 FY26, is fragile and highly dependent on the successful delivery of legacy projects in Denmark and the avoidance of new low-margin, complex custom orders. Management’s optimism about returning to historical performance levels hinges on winning new business in visual inspection and self-administration assembly, yet order intake remains slower than expected despite increased sales and marketing efforts. The segment’s guidance assumes a mid-single-digit to low-double-digit revenue decline for FY26, implying that any further deterioration in order conversion—potentially driven by prolonged customer CapEx scrutiny, increased competition from automation specialists, or macroeconomic hesitation in industrial spending—could push margins back into negative territory. Moreover, the segment’s historical profitability was bolstered by non-recurring, high-margin projects (e.g., the Not for Human Use fill-and-finish service), which are not repeatable and whose decline in Q1 FY26 was explicitly cited as a headwind. Without a sustainable pipeline of high-margin, standardized offerings, the Engineering segment’s current margin gains may prove temporary, leaving the company exposed to a prolonged drag on consolidated profitability that could offset gains from the BDS segment.

Timing of transfer of goods or services [axis] Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Geographical areas [axis] Breakdown of Revenue (2025)

Timing of transfer of goods or services [axis] Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical areas [axis] Breakdown of Revenue (2025)

Timing of transfer of goods or services [axis] Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password